"Every disease we target begins with a question: what's missing for the patient?" That ethos continues to shape Tarsus Pharmaceuticals Inc. (TARS) as it moves through the final quarter of 2025.
The company is navigating a pivotal stretch marked by clinical momentum and global regulatory activity, with multiple programs advancing toward Phase 2 trials and new market pathways opening abroad.
From eye care to infectious disease prevention, Tarsus is building out a portfolio aimed at conditions that remain underserved, and its pipeline reflects a steady cadence of progress across therapeutic categories.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.